Dr. Dick Menzies is the Director of Respiratory Medicine at the MUHC and a researcher in the Respiratory Health Axis and Health Outcomes Axis at the Research Institute of the MUHC. Watch his video and presentation on global TB control.
The World Health Organization (WHO) estimates that approximately one-third of the world's population are carriers of the latent form of the disease. Although these individuals show no symptoms and are not contagious, they can develop the active form of tuberculosis at any time. As a hidden reservoir of the disease, they represent the main obstacle to its eradication.
A team of researchers from the Research Institute of the McGill University Health Centre (MUHC) has received the largest grant ever awarded by the Canadian Institutes of Health Research (CIHR) for a clinical trial of latent tuberculosis (TB) therapy. The principal investigator: Dr Dick Menzies, together with Dr Kevin Schwartzman, Dr Andrea Benedetti and Dr Madhukar Pai from the Montreal Chest Institute of the MUHC were awarded $4.9 million for an international clinical trial that will study the effectiveness of a new treatment for latent TB that could help to eradicate TB worldwide.
Dr. Dick Menzies (bio)
Dr. Dick Menzies is the Director of Respiratory Medicine at the MUHC and a researcher in the Respiratory Health Axis and Health Outcomes Axis at the Research Institute of the MUHC. He is also a professor in epidemiology and biostatistics as well as respiratory medicine at the Faculty of Medicine of McGill University.
Poster: World TB Day at the Montreal Chest Institute (McGill University Health Centre)